A detailed history of Umb Bank, N.A. transactions in Novo Nordisk A S stock. As of the latest transaction made, Umb Bank, N.A. holds 41,430 shares of NVO stock, worth $3.61 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
41,430
Previous 41,764 0.8%
Holding current value
$3.61 Million
Previous $4.97 Million 28.34%
% of portfolio
0.06%
Previous 0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 16, 2025

SELL
$85.0 - $120.04 $28,390 - $40,093
-334 Reduced 0.8%
41,430 $3.56 Million
Q3 2024

Oct 08, 2024

SELL
$119.07 - $145.42 $53,343 - $65,148
-448 Reduced 1.06%
41,764 $4.97 Million
Q2 2024

Jul 29, 2024

SELL
$122.71 - $146.91 $371,811 - $445,137
-3,030 Reduced 6.7%
42,212 $6.03 Million
Q1 2024

Apr 26, 2024

SELL
$102.11 - $135.92 $130,598 - $173,841
-1,279 Reduced 2.75%
45,242 $5.81 Million
Q4 2023

Jan 23, 2024

SELL
$87.78 - $105.45 $116,132 - $139,510
-1,323 Reduced 2.77%
46,521 $4.81 Million
Q3 2023

Oct 18, 2023

BUY
$90.94 - $199.54 $2.17 Million - $4.76 Million
23,875 Added 99.61%
47,844 $4.35 Million
Q2 2023

Jul 25, 2023

BUY
$155.98 - $172.65 $34,939 - $38,673
224 Added 0.94%
23,969 $3.88 Million
Q1 2023

Apr 11, 2023

BUY
$132.34 - $159.14 $47,642 - $57,290
360 Added 1.54%
23,745 $3.78 Million
Q4 2022

Jan 10, 2023

SELL
$102.55 - $135.33 $42,045 - $55,485
-410 Reduced 1.72%
23,385 $3.17 Million
Q3 2022

Oct 13, 2022

SELL
$95.28 - $116.93 $63,932 - $78,460
-671 Reduced 2.74%
23,795 $2.37 Million
Q2 2022

Jul 20, 2022

SELL
$103.24 - $121.81 $47,490 - $56,032
-460 Reduced 1.85%
24,466 $2.73 Million
Q1 2022

Apr 22, 2022

SELL
$93.1 - $112.54 $3,724 - $4,501
-40 Reduced 0.16%
24,926 $2.77 Million
Q4 2021

Feb 09, 2022

BUY
$95.88 - $117.08 $2.39 Million - $2.92 Million
24,966 New
24,966 $2.8 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Umb Bank, N.A. Portfolio

Follow Umb Bank, N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Umb Bank, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Umb Bank, N.A. with notifications on news.